Daily Newsletter

22 August 2023

Daily Newsletter

22 August 2023

Qualifyze secures funds to transform pharma supply chain compliance

The company's supplier intelligence suite offers supplier compliance level statistics and audit data to pharma firms.

Vishnu Priyan August 22 2023

German compliance company Qualifyze has secured $12m in a financing round to improve supply chain compliance in the pharmaceutical sector using technological and audit data.

The funding round saw participation from current investors HV Capital and Rheingau Founders. New investors HarbourVest Partners and H14 also took part.

The company plans to expedite its transformation into an end-to-end supply chain compliance data platform. 

Established in 2019, Qualifyze offers supply chain compliance assessments to pharmaceutical companies.

The proceeds will aid the company in improving its cloud-based audit data and application platform that links auditors, customers and suppliers. These solutions enable tracking, observation and adherence to quality and sustainability compliance in the pharmaceutical industry.

Qualifyze’s supplier intelligence suite offers supplier compliance level statistics and audit data to pharmaceutical firms. This helps forecast trends and create compliance risk mitigation approaches.

The company also intends to use the additional funds to expand its footprint in existing and new markets geographically.

Qualifyze CEO and founder Dr David Schneider stated: “Qualifyze is creating a new category of compliance data, which will allow our clients to make more informed decisions to increase drug safety for their patients and to better allocate investments into supply chain compliance, even beyond GxP [good practice]. 

“This funding will help us accelerate our mission to transform supply chain compliance in healthcare in a sustainable, data-driven manner.”

Multiple Myeloma (MM) pipeline is dominated by CAR-T cells

The success of CAR-Ts in MM has fueled R&D investment into this class of therapy, with more CAR-Ts in development than all other cell and gene therapy classes combined. The approval of the autologous CAR-T cell therapies Abecma and Carvykti sees the CAR-T pipeline mostly constituted of autologous drugs. However, there are also multiple allogeneic CAR-Ts in the pipeline, with these therapies having an “off-the-shelf” advantage over autologous therapies.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close